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Only a few short years ago, viral load (HIV-1
RNA) testing was introduced as a new tool for
HIV management. Many physicians, inside cor-
rections as well as outside, delayed implement-
ing the test.  Though most of the arguments
against its use included lack of standardization,
inability to process specimens and shortage of
specialists to interpret and utilize results in HIV
management, the major unspoken obstacle was
cost.  In 2000, we now face a similar situation
with antiretroviral resistance testing. Despite
national guidelines for their use as the commu-
nity standard of care in the US and favorable
retrospective and prospective data, few correc-
tional systems have embraced genotypic or
phenotypic testing. This article will address spe-
cific issues in the use of resistance testing and
provide an overview of clinical studies and
potential application for their use.
Defining Resistance: The Causes
of Viral Rebound
The presence of antiretroviral resistance to HIV
medications may be signaled clinically by the
observation of viral rebound.  Viral rebound can
be defined as any reproducible increase in the
viral load determined to be threefold or greater
that is not due to acute intercurrent infectious ill-
ness or vaccination. It is important to note that
not all rebound phenomena are related to drug
resistance.  In fact, the most common cause of
rebound is poor adherence.  In studies of viro-
logic rebound occurring in patients receiving a
triple combination including a protease inhibitor,
the largest percentage demonstrate no muta-
tions at all, followed by mutations to the nucleo-
side reverse transcriptase inhibitor and then to
the protease inhibitor. 
Resistance is the result of two major character-
istics of HIV:  1) its rapid turnover rate; and 2) its
error prone RNA replication process. HIV lacks
a proofreading function that corrects the mis-
takes in viral replication that result in mutations.
Within a given patient, HIV exists as a combi-
nation of multiple strains (quasispecies) that
diverge from the original wild-type or unmutated
virus.  The quasispecies differ based on
acquired mutations that are passed onto daugh-
ter viruses.  
Most mutations that occur naturally in the
course of viral replication result in no effect on
viral susceptibility to ART, while others lead
to death of the virus.  In order to cause clinical-
ly important resistance, a mutation must:
1) decrease the viral sensitivity to the drug,
2) become the dominant quasispecies because
of increased viral fitness in the setting of selec-
tive drug pressure, and 3) provide a competitive
advantage over the wild-type of the virus and
maintain viral replication by preserving enzyme
function. If one of several quasispecies has a
mutation that results in resistance to a specific
drug, then exposure to that drug acts as a
selective pressure that allows the resistant qua-
sispecies to replicate freely while the other qua-
sispecies and wild-type virus that lack the resis-
tance mutation are suppressed.  The resistant
quasispecies then becomes the predominant
replicating strain. Clinically, the patient’s viral
load increases and treatment fails. The patterns
and types of mutations associated with NRTIs,
NNRTIs and PIs are described in the HIV 101,
page 5.
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The key to understanding the limitations of
resistance testing is understanding that
resistant quasispecies become the domi-
nant strain when HAART is being used,
while other forms of the virus are sup-
pressed, including those that might be
resistant to other drugs.  That is, resistance
to a given drug may not be detected if the
patient is not taking that drug at the time
that a resistance test is given.  Since the
selective pressure that favors replication of
the resistant quasispecies over the suscep-
tible strains has been removed, there may
not be enough of the resistant quasispecies
present to be detected by current resis-
tance assays.  Yet the resistant strain will
rapidly re-emerge if the selective pressure
(the drug) is re-instituted. Thus, knowledge
of prior antiretroviral treatment may steer a
clinician away from a drug that might
appear effective when the results of resis-
tance assays are interpreted without knowl-
edge of prior treatment history.
Resistance to drugs may decrease the abil-
ity of the virus to replicate, as has been
reported by a number of investigators. Drug
resistance is associated with impaired pro-
tease and reverse transcriptase (RT) func-
tion and reduced replication capacity. In
one report, Nelfinavir resistant viruses
exhibited many protease cleavage defects
and 70% of Nelfinavir-resistant viruses
showed large reductions in viral replication
(1). In addition, some viruses exhibit hyper-
sensitivity to selected drugs after develop-
ing mutations (2). 
Genotyping versus 
phenotyping
Resistance is measured by two methods:
genotyping and phenotyping.  Commercial
assays using both of these methods are
available. For example, TruGene (Visible
Genetics) and ViroSequ (PE Applied
Biosystems) provide genotyping informa-
tion, and AntiVirogram (Virco) and
PhenoSense (ViroLogic) provide phenotyp-
ing information.  Genotypic assays provide
information on mutations in the genes cod-
ing for reverse transcriptase and protease
that confer drug. Phenotypic resistance is a
direct measure of sensitivity and is similar
to our current antibiotic sensitivity testing
practices.  Phenotypic assays rely on
changes in the IC50, the minimum inhibito-
ry concentration of the drug required to
decrease viral replication by 50% in the
particular cellular system used.  The emer-
gence of resistance is signaled by a signifi-
cant increase in IC50 over baseline (3, 4).
Both genotyping and phenotyping are com-
plex technologies that utilize the poly-
merase chain reaction and other molecular
techniques.  They require specialized facil-
ities staffed by well-trained laboratory per-
sonnel. Commercial assays using both
methodologies are available, and the turn-
around times for results are 1-2 weeks for
genotyping and 2-4 weeks for phenotyping.
It is important to note that a plasma HIV
RNA level above 1,000 copies/mL is neces-
sary for either method to produce reliable
results.  Furthermore, neither method can
routinely detect minority quasispecies;
therefore, some resistant strains of virus
may be missed.  Although both types of
assays are reproducible, both intra- and
interlaboratory variability may be greater
with genotypic assays.  With regard to
interpretation of results, complex mutation-
al patterns detected by genotyping fre-
quently require the interpretation of an
expert whereas the results of phenotypic
assays may be more easily interpreted by
treating physicians. Phenotypic assays
generally cost more than genotypic (3).
Interpreting Genotypic and
Phenotypic Resistance
Assays
Interpretation of genotypic assays requires
not only knowledge of the individual muta-
tions, which confer resistance and cross-
resistance to drugs within the same class,
but also an understanding of the interac-
tions of multiple resistance mutations.  For
example, a single mutation in the protease
gene may confer high-level resistance for
one PI, yet for another, it may require mul-
tiple mutations to confer resistance.
However, the phenotypic expression of a
combination of genotypically detected
mutations cannot always be predicted (3).
To address this issue, Virco (Mechelen,
Belgium), a manufacturer of one commer-
cially available genotypic assay, has used a
relational database of over 10,000 clinical
isolates of HIV for which genotypic and
phenotypic results are known, to assign a
"virtual phenotype" to viral isolates based
on mutational patterns.  How this virtual
phenotype correlates with response to anti-
retroviral therapy must be explored with
appropriately designed clinical trials (5).
Interpretation of phenotypic assay results
suffers from a lack of clinical information
regarding correlation of fold increase in
resistance to in vivo activity of the various
antiretroviral drugs.  For example, a small
fold increase in resistance to a protease
inhibitor may be overcome by increasing
serum levels of the protease inhibitor (3).
Using Resistance Testing in
Clinical Practice
The DHHS/Kaiser Guidelines (4) for using
antiretroviral agents recommend that resis-
tance assays be used to modify antiretrovi-
ral therapy in the setting of virologic failure
during ongoing HAART and in the case of
suboptimal viral suppression after initiating
a new regimen. Resistance testing should
also be considered in antiretroviral naïve
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STUDY
GART
VIRADAPT
VIRA 3001
Melnick et al.
NARVAL
N
153
108
221
115
541
PRIMARY ENDPOINT
Change in viral RNA (at wk. 8)
Change in viral RNA(at wk. 24)
Achieving VL <400 copies/mL
(at wk. 16)
Decline in viral RNA
(at wk. 4, 16)
HIV RNA <200 (at wk. 24)
OUTCOME
Decline in viral RNA
Group A: -1.12 log
Group B: -0.52 log
Decline in viral RNA
Group A: -1.15 log
Group B: -0.67 log
Observed Data: 
59% of Group A had VL<400,
42% Group B had <400.
At 4 wks, decline in viral RNA:
Group A: -1.0 log 
Group B: -0.5 log (at wk. 16, no
significant difference)
No significant difference
Table 1. Studies of the Value of Resistance Testing in Creating Successful ART
All studies compared regimens based on resistance testing (Group A) versus standard of 
care (Group B).
GENOTYPING STUDIES
PHENOTYPING STUDIES
GENOTYPING, PHENOTYPING AND SOC STUDIES
Dear Colleagues,
Hello Alaska! Hello Arkansas! Hello North Dakota! I have just reviewed our list of subscribers, and I
was amazed and humbled by the breadth and depth of the list. We reach more than 2,300 of you in
all 50 states and several countries. You are physicians, nurse practitioners, pharmacists, and AIDS
educators, who work on the front line of HIV care and interface with the HIV-infected inmate. I am
thrilled that so many correctional providers want to be updated on HIV and Hepatitis and I am hon-
ored by your trust in this educational newsletter. This publication reaches a great network of cor-
rectional healthcare providers, binds us, and weaves us together in a web of influence. Together, we
are making change in correctional HIV care.
Collectively, we care for almost one-fifth of the nations’ HIV-infected individuals in correctional clinic
settings. We take care of one-third of the nations’ Hepatitis C-infected patients. We see more STDs,
TB, and mental illness than community providers could ever imagine. We do this within the confines
of prison and jail walls, usually at a distance from academic medical centers, and even farther from
easy access to medical technology. Because of our isolation from the community, we must often rely
on our clinical skills to treat and triage patients.
In the 12 years that I’ve been working as an HIV provider in correctional settings, I’ve seen - and
heard about - a great deal of change. Correctional HIV care in the U.S. is moving toward, and in
some cases beyond, the community standard. Certain institutions provide an exemplary level of
care. More important, links between prisons and jails and the community are growing. From the
medical perspective, the walls of correctional facilities are becoming more porous; meaning that
medical education and treatment advances are reaching inside, and - perhaps more importantly -
information about the work we do and our patients in need is reaching the outside world. 
This issue marks our second anniversary at HEPP News! In our third year of publication, we pledge
to continue to bring you the latest in HIV and Hepatitis management, written by correctional profes-
sionals with hands-on experience providing patient care in correctional facilities.
After reviewing this issue of HEPP News, readers should understand how to incorporate resistance
testing into HIV care, identify when resistant strains of HIV are signaled clinically, list the newest
treatment strategies for Molluscum contagiosum, and describe the latest  news on antiretrovirals.
Last but not least, be sure to update your subscriber information - if you’d like to receive the newslet-
ter by email, in pdf format (can be read on all types of computers), please let us know. We can fax
you AND email you the newsletter if you prefer both formats. Dont forget to visit us for online
archives of HEPP News at www.hivcorrections.org.
We love to hear from you and we accept written contributions. Please write, email, fax, or call!
Sincerely,
Anne S. De Groot, M.D.
Letter from the Editor
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4patients with acute HIV infection for whom
treatment is planned.  Suppression of viral
replication during acute HIV infection may
favorably alter the long-term course of HIV
infection by allowing the immune system to
develop antiviral responses that are other-
wise impaired by unchecked viral replication
during acute infection.  This accounts for the
recommendation of resistance testing for
naïve patients with acute HIV infection, but
not for naïve patients with established,
chronic infection.
Studies Reveal Effectiveness
of Resistance Testing
Several prospective studies provide informa-
tion on the clinical utility of using HIV-1 resis-
tance assays to direct therapy in patients
who are failing an antiretroviral regimen.
See Table 1 pg.2 for a summary.  The GART
(6) and VIRADAPT (7) studies used geno-
typic resistance assays.  In the GART study,
at eight weeks, the mean decline in HIV
RNA was significantly greater in the group
whose regimens were based on resistance
testing than in the SOC group (-1.12 log vs.
-0.52 log). Fifty-five percent of those in the
resistance testing-based group had a viral
load <500 copies/ml versus 25% in the SOC
group. In the VIRADAPT study, at six
months, the resistance testing group had a
significantly greater decline in viral load than
the SOC group (-1.15 log v. -0.67 log).
The VIRA 3001 Study (8) and a study report-
ed by Melnick, et al. (9) used phenotypic
resistance assays to direct a change in anti-
retroviral therapy. Using intent-to-treat
analysis in which patients lost to follow up
were counted as failures, the VIRA 3001
Study found no significant difference
between the groups in the primary endpoint.
In an alternative analysis using observed
data, there was a significant difference in the
groups (59% of those in the resistance-test-
ing group had a viral load <400 copies/mL v.
42% in the SOC group, Melnick et al.) At four
weeks, there was a statistically greater
decline in viral RNA in the resistance-testing
group than in the SOC group, but the differ-
ence was not sustained at 16 weeks.  These
two studies were conducted with participants
who were more highly treatment-experi-
enced than those in GART and VIRADAPT.
Therefore, the number of available active
agents was limited, particularly in the study
reported by Melnick et al. in which even
those on resistance-testing-based-regimens
were on an average of less than three active
drugs.  This fact must be taken into account
when interpreting these studies.
In the NARVAL study, 541 (10) highly treat-
ment-experienced patients failing a 3 drug
protease inhibitor containing regimen were
randomized to therapy based either on
genotyping, phenotyping, or SOC. At week
24, a greater percentage of participants in
the genotyping-based group had HIV-1 RNA
levels less than 200 copies/mL, but the dif-
ference was not statistically significant.
Although short in duration, GART and
VIRADAPT clearly support the use of resis-
tance assays to help direct antiretroviral
therapy.  VIRA 3001 and the study reported
by Melnick, et al. are equivocal, while NAR-
VAL does not support resistance testing.
Because participants in these last three
studies had greater prior treatment experi-
ence than in GART and VIRADAPT, one
interpretation of these data is that resistance
testing is less useful in highly treatment-
experienced patients with few treatment
options.  Thus, one clear indication for use of
resistance testing is after the first regimen
fails.
Conclusion
In summary, the use of both genotypic and
phenotypic resistance assays is expanding
in clinical practice. Although specialized
facilities and personnel are necessary to
conduct these tests, commercially available
kits have made the results reproducible,
available in a timely fashion, and relatively
affordable.  Resistance testing to guide mod-
ifications in ongoing therapy is recommend-
ed in the setting of antiretroviral failure when
a new regimen is anticipated and also in the
setting of incomplete suppression of viral
replication by a new regimen. It should also
be considered when the decision is made to
treat acute HIV infection.  Several prospec-
tive clinical trials have demonstrated better
suppression of viral replication in patients
whose antiretroviral regimen has been guid-
ed by resistance testing, particularly in
patients whose exposure to prior antiretrovi-
ral therapy has been limited, i.e. after the
first regimen fails. Despite this benefit, resis-
tance testing information must be combined
with a complete medical history that details
prior regimens, side effects to medications,
and adherence with treatment.  Such infor-
mation is essential in selecting a regimen
that is not only effective in suppressing viral
replication but also acceptable to the individ-
ual patient.
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PROTEASE INHIBITORS
HIV Medications and Gene Mutations
Primary mutations are those that are associated with high-level resistance to an ART.  Secondary mutations include
those that alter conformation such that viral fitness is modified but not high-level resistance.  For patients who are sus-
tained on partially suppressive therapy for prolonged time periods, additional compensatory mutations may develop.
This list of primary and secondary mutations for each available ART is listed below.  This chart will be updated in future
issues as new information is described.
Amino acid changes in the viral enzyme system are the result of a mutation.  Such changes may be in the form of substitu-
tions, insertions or deletions.  Mutations are also classified as primary and secondary.  Primary mutations typically arise first
in response to therapy with a particular antiretroviral agent.  Primary mutations are drug specific and typically interfere with
the binding of the drug to the viral enzyme.  The extent to which the mutation alters the binding of the drug to the enzyme
directly influences the reduction in IC50.  Secondary mutations accumulate during continued therapy with a given drug and
usually potentiate the effect that the primary mutation had on drug binding.  Secondary mutations have a less dramatic effect
on increasing the IC50, however may significantly affect cross-resistance.  For instance, if a patient remains on a non-sup-
pressive, PI-containing regimen for considerable time in the setting of a high viral load, the number of secondary mutations
increases and may adversely affect the ability to use another PI in salvage therapy.
The occurrence of cross-resistance has resulted in many clinicians adhering to the concept that the first regimen will be the
most effective regimen or the first shot is the best shot.  Therefore clinicians, when possible, should select regimens with a
high genetic barrier for developing resistance.  This must be tempered by selecting regimens that are simple and have few
side effects.  These competing paradigms often require clinicians to frequently monitor viral load and change regimens quick-
ly after viral rebound to avoid the development of cross resistance.  Resistance testing may aid in the decision for altering an
antiretroviral regimen in such settings.
ANTIRETROVIRAL
ALL NRTIS
Zidovudine (AZT, ZDV)
Didanosine (DDI)
Zalcitibine (DDC)
Stavudine (D4T)
Lamivudine (3TC)
Abacavir (ABC)
Nevirapine (NVP)
Delavirdine (DLV)
Efavirenz (EFV)
Saquinavir (SQV)
Indinavir (IDV)
Ritonavir (RTV)
Nelfinavir (NLF)
Amprenavir (APV)
NNRTIS
Updated HIV Drug Resistance Testing Guidelines, published by
the International AIDS Society, USA Part II.
http://jama.ama-assn.org/issues/v283n18/full/jst90018.htm
The AIDS Gateway to the Internet
http://www.aids.org
AIDS Medications Information
http://www.aidsmeds.com
UK National AIDS Manual/ British HIV Association
http://www.aidsmap.com
Physicians Research Network
http://www.pnr.org
7th Conference on Retroviruses and Opportunistic
Infections
http://www.retroconference.org
Web Resources
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When to Genotype in the Management of Drug Resistance 
Among HIV-infected Inmates
HIV-Positive Patient
Naïve (no previous ART)
Chronic Infection
(>3 years)
Recent Infection 
(within 3 years)
Experienced
Evaluate and treat
for HIV. 
Dont genotype.
HIV source 
known?
Consider 
genotyping*
Source on ART?
Select ART regimen
using drugs the HIV
source did not
receive.
Consider 
genotyping
Continue monitoring
viral loadGenotype
Concern about 
infection with 
resistant virus?
Evaluate and treat
for HIV if appropri-
ate. (Probably no
need to genotype.)**
UnknownKnown
Not responding to
HAART, 
(VL>1000 copies/mL)
Responding to
HAART, 
(VL<1000 copies/mL)
Adherent? Continue HAART
New regimen
available?
Reinforce adherence
and continue to
monitor viral load
and CD4 T-cell
count
Repeat viral load
measurement
G Consider genotyping
G Implement regimen
G Monitor viral load
VL>1000 copies/mL?
(Necessary for 
genotyping to be 
carried out.)
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XIIIth International AIDS
Conference Continued: 
The Difficulty of Deep
Salvage
The International Conference on
AIDS is the premier venue for pre-
sentation of HIV-related research
from all over the world. The last
issue of HEPP News covered the
prison-related data, and some of the
medical reports. This article will
review the important data regarding
the care of individuals with access
to potent HIV therapies.  
In areas where combination anti-
retroviral agents have been avail-
able, there are still persistent ques-
tions regarding the care of the treat-
ment naïve patient as well as the
patient whose treatment meets viro-
logic failure. New data related to
each of these areas could be found
at the conference and, while unex-
pected or spectacular headline-
making results were not announced,
several instructive lessons for
providers and patients were pre-
sented.
As discussed in the main article, an
increasingly frequent conundrum
confronting clinicians is the man-
agement of the highly treatment
experienced patient.  Most studies
to date have demonstrated that suc-
cessful virologic suppression of
such patients is difficult to achieve
regardless of the choice of agents
employed. Aggressive attempts to
regain control of viral replication by
using multiple antiretrovirals in com-
bination, so called ’megaHAART’,
have had some better results.
Follow-up data from one of the few
mavens of megaHAART, Julio
Montaner, were presented at
Durban.  Overall, using combina-
tions of up to 8 antiretroviral agents
in heavily treatment experienced
patients in Vancouver, approximate-
YesNo
NoYes
YesNo
NoYes
If genotype appears
to leave no options,
consider phenotyping
Determine new 
regimen
LowHigh
Important Correction from July/August 2000 issue: in the HEPPigram,
VCG IgG antibody positive patients are immune, contrary to what we printed.
VCG IgG antibody negative patients should follow the remaining path in the
flow sheet.
*For more information on baseline HIV resis-
tance rates, see 6th Conference on
Retroviruses and Opportunistic Infections,
Abstract 272. www.retrovirus.org/99
**For advice on initiating ART in acutely HIV-
infected patients, see Carpenter CCJ et al.,
JAMA 1/19/00; 283(3):381-390.
Treatment
Updates
Continued on page 7
An increasingly frequent
conundrum confronting 
clinicians is the management
of the highly treatment- 
experienced patient.
7Ask the Expert
Dr. Feller: In Rhode Island, as in other state
correctional systems, we’ve observed a high
prevalence of HCV and HIV co-infection in
incarcerated populations.   With highlly active
antiretroviral therapy (HAART) and a subse-
quent decline in mortality from opportunistic
infections in HIV,  hepatic failure is likely to
increase as a leading cause of death in incar-
cerated patients. Co-infection with HIV raises
particular treatment issues.  
For example, we’ve observed that co-infect-
ed patients on combination therapy tend to
have more problems with ribavirin-associat-
ed hemolytic anemia and interferon-related
thrombocytopenia than patients who are not
co-infected. Monitoring will detect which
patients develop anemia (hemoglobin <10-11
grams %), that can be treated with erythro-
poiten at dose of 40,000 units weekly.
Although patients have slightly more difficul-
ty tolerating therapy, HCV treatment does
clear HCV RNA from serum in a portion of
patients who have HIV co-infection, similar to
non co-infected patients. 
Occasionally, patients will experience hepa-
totoxicity when an HIV regimen is instituted.
Treating HCV first to suppress viral activity
may permit the introduction of HIV drugs with
less hepatotoxicity.
Certain HIV treatments are more toxic when
used in combination with HCV. For example,
the protease inhibitor ritonavir is most hepa-
totoxic, followed by indinavir. Sacquinavir
and nelfinavir are generally better tolerated.
HIV treatment is generally introduced first
because HIV may be more rapidly progres-
sive.  At times, severe hepatic disease may
necessitate early HCV therapy, allowing sub-
sequent introductions of HIV drugs with
decreased hepatotoxicity.
Q: What types of HCV treatment-related
issues arise with HIV-infected patients that
are not different from other patients?
Dr. Feller: Interferon-related depression is
real and can be fatal. Should depression
reoccur here, the ID consultant should select
serotonin re-uptake inhibitors, monitor men-
tal status, and  not withhold anti-HCV thera-
py for well-controlled depression.
Q: What findings do you consider "new" and
important for our audience, that might also be
relevant to this case?
Dr. Feller: This patient has moderate fibro-
sis. He may not completely recover from
HCV infection, however there is recent evi-
dence that some patients who do not clear
HCV-RNA from serum may have interferon-
related improvement in liver fibrosis.   Some
research has suggested that even if interfer-
on does not clear the virus, maintenance
therapy may decrease or stabilize hepatic
fibrosis and prevent end-stage cirrhosis.
(See News Flashes on page 8.)
Q: What other concerns exist in the treat-
ment of HCV in HIV-infected patients?
Dr. Feller: Be wary in initiating anti-retroviral
therapy of "immune reactivation" flare up
(HCV patients started on anti-HIV therapy
may get hepatomegaly, upper abdominal
pain, deterioration of liver function).  Also
watch for drug hepatotoxicity, and immune
system reconstitution.
For more information on the management of
Hepatitis C, see HEPP News Vol. 3, Issue 6,
June 2000 at http://www.HIVcorrections.org.
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Dr. Feller, of Miriam Hospital and Clinical Professor of Medicine at Brown University,
Providence, contributed the following case. Dr. Feller is a hepatologist who provides expert
consultation to HIV practitioners who wish to treat their HIV and HCV co-infected patients for
Hepatitis C.
ly 40% of subjects who could tolerate
these intensive regimens had HIV RNA
levels below 400 copies/mL at one year.
As expected, intolerance and toxicity
were high and resistance testing predict-
ed success.  MegaHAART remains an
option for select patients for whom treat-
ment cannot wait until the release of new
drugs.  However, extreme caution must
be used when combining these agents
to minimize drug interactions and seri-
ous toxicity.
For many patients with multiple antiretro-
viral experience and resistance, new
drugs offer the only hope to regain viro-
logic control.  One of the most talked
about drugs on the horizon is ABT-378/r
or lopinavir - recently christened with the
trade name Kaletra.  This drug is actual-
ly a combination of two protease
inhibitors, ABT-378 400 mg plus 100 mg
of ritonavir - the latter, included to
increase plasma concentrations of the
former.   Several posters reported on the
potency of this agent including treatment
of multiple drug experienced patients
(TuPeB3196, TuPeB3197, TuPeB3198).
In one study by Clumek et al. of 57 sub-
jects with extensive NRTI and PI experi-
ence but who were all NNRTI naïve,
EFV and a NRTI chosen by the investi-
gator plus one of two doses of
lopinavir/ritonavir (400/100 versus
533/133) were studied.  In an intent to
treat analysis, 69% of the lower dose
arm and 80% of the higher dose arm
achieved viral loads below 400
copies/mL (TuPeB3196). Additionally,
the drug appears to be effective despite
predicted resistance by genotype and
phenotype testing.  Diarrhea and nau-
sea are the major toxicities associated
with lopinavir.  The ritonavir component
may present problems for maintenance
of normal blood lipids.   
Other new agents discussed at the
conference, which appear promising
include: T-20, an injectable HIV fusion
inhibitor that continues to maintain good
responses out to 48 weeks of study
follow-up and DAPD another guanosine
analog (like ABC) that may actually have
activity against multi-nucleoside resis-
tant virus.  (For more information on
the conference and abstracts, visit
www.aids2000.org).
Treatment
Updates... 
(continued from page 6)
HEPP News Expert Case: A 34-year-old male intravenous drug user with well-controlled
AIDS and abnormal alanine transferase is seen in Infectious Disease clinic at the prison.
His T cell count is 250, and he has had several consecutive undetectable viral loads (<50)
by RNA PCR over the past 6 months. His HIV is controlled with DDI, D4T, Efavirenz; he
takes his DDI on his own in the morning (two concentrated formulation 200 mg tablets) and
receives the other two medications by DOT at the medline window. 
The ID consultant obtains an HCV antibody test, which is positive. After discussion, it is
clear that the patient will be remaining in prison until his maximum sentencing date two
years hence. He is currently enrolled in a drug "recovery" program at the prison, and he
willingly states that he is committed to a life without drugs and alcohol. He has a history of
depression, and was on serotonin-uptake inhibitors in the past, but he claims that this is
"under control" right now and doesn’t want to take any "mood altering drugs" while he’s in
the drug recovery program.
A liver biopsy is ordered and approved by the URC after careful review. The biopsy reveals
moderate fibrosis. Combination treatment for HCV with interferon/ribavirin is initiated.
What concerns would you have, as the HCV expert, about his course of treatment?
For many patients with multiple
antiretroviral experience 
and resistance, new drugs offer
the only hope to regain 
virologic control.
United States Conference on AIDS 
October 1-4, 2000 
Atlanta, GA
Contact: Oscar Medrano, Conference
Registrar, National Minority AIDS 
Council, 1931 13th St NW, Washington
DC 20009-4432 
Call: 202.483.6622 x 343 
E-mail: omedrano@nmac.org or
info@nmac.org 
Management of HIV/ AIDS in the
Correctional Setting: A Live 
Satellite Videoconference Series, 
Antiretroviral Update 2000
October 3, 2000
12:30- 3:30 E.S.T.
2.5 CME credits available
Call: 518.262.6864
Email: santosm@mail.amc.edu
View this talk on your computer! 
In November, you’ll be able to 
visit the HEPP News website at
www.HIVcorrections.org, to 
download and view the above video 
conference at your convenience.
Thirteenth Annual Conference
Association of Nurses in AIDS Care
Chasing a Changing Tide: Complex
Clients, Care, and Communities
November 2-5, 2000 
Caribe Hilton San Juan, Puerto Rico
Contact: Sande Gracia Jones
958 Whitehall Ln., 
Orlando , FL 33019 
Call: 305.493.6734
Fax: 305.567.4319
Email: sj394@ starnet.com 
http://www.anacnet.org/
anacabstracts.htm
National STD Prevention Conference
December 4-7, 2000
Milwaukee, WI  
Contact: Glenda Vaughn, Centers for
Disease Control and Prevention 
Call: 404.639.1806 
E-mail: ghv1@cdc.gov 
Medical Management of AIDS: A
Comprehensive Review of HIV
Management - Winter Symposium
December 7-9, 2000
San Francisco, CA
Contact: Cliff Brock
Department of Medicine UCSF
Box 0656
San Francisco, CA 94143-0656 USA
Call: 415.476.5208
Fax: 415.476.3542
Email: cme@medicine.ucsf.edu
Web: http://medicine.ucsf.edu/
programs/cme
Save the 
Dates
News Flashes
Treating STDs Could Reduce HIV
Transmission by 27 Percent
Dr. Richard Rothenberg of the Ad Hoc STD/HIV
Transmission Group found that identifying and
treating people who have both HIV and another
sexually transmitted disease (STD) could
reduce the risk of HIV transmission to an unin-
fected person by 27 percent.  Data from eight
clinics across the United States on more than
4,500 HIV- and STD-infected individuals
showed that the decrease in possible HIV trans-
mission ranged from 10 percent in Los Angeles
to 38.1 percent in Colorado Springs. (STD,
August 2000;27:411-416).
Success Against Molluscum 
Contagiosum Virus (MCV) Noted
Recently, doctors at the National Cancer
Institute in Bethesda, MD, reported some suc-
cess against MCV (Molluscum contagiosum
virus) lesions using the antiviral drug cidofovir
(Vistide). MCV can cause disfiguring lesions on
the face, neck and genitals of people with
HIV/AIDS. There is no therapy specifically
licensed by the FDA for the treatment of MCV
lesions, but doctors have used, with varying
degrees of success, the immune boosters
Aldara (imiquimod) and DNCB, liquid nitrogen,
electric "zapping" of lesions and Retin-A. A
recent study reviewed the cases of two young
HIV-infected boys: one 4-year-old (CD4+ count
of 168 and viral load of 430,000 copies), and
one 8-year-old (CD4+ count of 329 and viral
load of >700,000). Despite the fact that both
boys had been receiving HAART for two years,
hundreds of MC lesions had developed on their
bodies. Using a skin treatment consisting of 15
grams of cidofovir with 22.5 grams of Dermovan
ointment, the doctors treated the skin lesions
once daily for five consecutive days each week,
for eight weeks.  After two months of cidofovir
therapy the MC lesions cleared and have not
returned after 18 months of monitoring.
(Archives of Dermatology 2000;136:983-985).
Two Important Follow-Ups on HCV
Liver Fibrosis
At the 4th International Workshop on HIV Drug
Resistance and Treatment Strategies, N.
Shulman of Stanford University reported on
"Histologic improvements of liver despite viro-
logic failure of interferon  (IFN)+ribavirin therapy
in 3 HIV+/HCV+ patients." Following up from
our Hepatitis C issue in June, this was a refer-
ence we could not locate showing the link
between treatment and improved post treatment
liver biopsy regardless of stage of disease. In
an ongoing treatment trial of IFN alpha, 3 mil-
lion  units TIW +  ribavirin 800mg/d , 3 patients
with virologic failure at 6 months received pre-
and post-therapy liver biopsies.  As has been
shown in HIV- HCV+ patients, treatment  of
HCV with interferon-based therapy can lead to
histologic benefits  despite lack of HCV clear-
ance or ALT normalization. Biopsy outcomes
should be an important part of future therapeu-
tic trials for  these patients. 
M Putoi from University of Brescia, Italy, pre-
sented "Liver Fibrosis progression is related to
CD4+ cells depletion in patients with Hepatitis C
and Human Immunodeficiency Virus
Coinfection."  The relationship between  the
stage of liver fibrosis and CD4 levels was ana-
lyzed taking into account the variables known or
suspected to influence liver  fibrosis progression
by using polytomous logistic regression. The
authors concluded that CD4 cells depletion is
independently associated with the severity of
liver fibrosis in chronic Hepatitis C. Antiretroviral
combination therapy aiming at keeping high
CD4 counts should be regarded as a priority in
the care of HIV and HCV coinfected patients.
(Reports from the 4th International Workshop
on HIV Drug Resistance and Treatment
Strategies, Sitges, Spain, June 12-16, 2000).
Inmate Adherence Videotape Series:
A Strategy to Increase HIV/AIDS
Medication Adherence in Correctional
Settings
Comprised of five videotapes, this series aims
to increase HIV-infected inmates’ awareness of
their disease and treatment with the ultimate
goal of reducing the progression of HIV
observed in correctional medical units.
Additionally, these tapes may encourage cost of
savings for correctional facilities by reducing the
expenses associated with treating preventable
complications of HIV. $40.00.  Contact Albany
Medical College at 518/ 262. 6864 or 
santosm@mail.amc.edu
Pocket Guide to HIV/AIDS Treatment
is available from the Hopkins HIV Report. The
guide was created for the AIDS Education and
Treatment Center’s National Resource Center, a
project sponsored by HRSA. To obtain a copy,
contact your regional AETC, or visit
http://www.aids-ed.org.
A New Treatment Directory through the
National Institutes of Health Clinical Center of
Pharmacology is available at:
http://www.cc.nih.gov/phar
Free CME materials are available through
the Healthcare Consortium
http://www.hivcme.org
Resources & Opportunities
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Oct. 31, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The 184 mutation confers resistance to which antiretroviral drug?
a) Stavudine (D4T)
b) Zidovudine (ZDV, AZT)
c) Lamivudine (3TC)
d) Nevirapine (NVP)
2. Which of the following HIV antiretrovirals are reported to be well-
tolerated in the presence of HCV treatment?
a) ritonavir
b) indinavir
c) saquinavir
d) Abacavir 
3. In which of the following situtations is resistance testing recom-
mended? 
a) For ART naïve patients with established, chronic 
infection
b) For ART naïve patients with acute HIV infection
c) In the case of suboptimal viral suppression after 
initiating a new regimen
d) a and b
e) b and c 
f) None of the above
4. Not all viral mutations cause clinically important resistance to ART.
Which of the following mutations cause clinically significant
resistance? 
a) Mutations that become the dominant quasispecies 
because of increased viral fitness in the setting of selective 
drug pressure
b) Mutations that provide a competitive advantage over the 
wild-type of the virus and maintain viral replication by pre
serving enzyme function.
c) Mutations that increase viral sensitivity to the drug
d) a and b
e) all of the above
5. How is the presence of antiretroviral resistance to HIV medications
signaled clinically?
a) reduction in CD4 count
b) any reproducable three fold or greater increase in viral 
load in any patient who is adherent
c) Significant increase (VL>50mL) in viral rebound in any 
patient who is adherent
d) Significant fluctuation of CD4 count
6. According to a recent report, which of the following treatments are
FDA approved for use against Molluscum contagiosum? 
a) immune boosters Aldara (imiquimod) 
b) DNCB
c) electric "zapping" of lesions 
d) Retin-A
e) the antiviral drug cidofovir (Vistide)
f) none of the above
g) all of the above  
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Treatment
Updates 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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